Biofluidic chip technology for studying sickle cell disease
Official title: Sickle Cell Disease (SCD) Biochip': Towards a Simple and Reliable Way to Monitor Sickle Cell Disease
Run by University Hospitals Cleveland Medical Center · NCT02824471 · Data updated 2026-11-12
This study is testing a new technology that looks closely at the cells of people with sickle cell disease to better understand how their cells behave and interact.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 12 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | University Hospitals Cleveland Medical Center Academic / other |
| Locations | 1 site (Cleveland, Ohio) |
| Status | Recruiting |
| Started | October 2014 |
| Main results expected | May 31, 2030 |
| Study ends | May 31, 2030 |
| Registry record updated | September 11, 2026 |
| Trial ID | NCT02824471 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include males and females aged 12 years and older with a documented diagnosis of sickle cell disease.
✕Probably not a fit
Patients with conditions that may compromise their safety or the quality of the data will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to utilize novel biofluidic chip technology to investigate the surface characteristics of cells in patients with sickle cell disease (SCD). By capturing cell populations without extensive processing, the SCD biochip allows for a systematic examination of cellular membrane properties and activation status. The study seeks to enhance understanding of the interactions and abnormalities associated with SCD across various clinical phenotypes. This innovative approach could provide insights that traditional methods may overlook.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of sickle cell disease.
How similar studies have gone: While similar biofluidic technologies have been explored, this specific application in sickle cell disease is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria * Male or female ≥12 years of age at the time of consent (enrollment). * Documentation Sickle Cell Disease, including HbSS or compound heterozygus HbSC- or HbSβ- thalassemia diagnosis as evidenced by one or more clinical features. * Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study. Exclusion Criteria * Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Where it's running
-
University Hospitals Case Medical Center
Cleveland, Ohio, United States Recruiting
Study contacts
- Principal investigator: Amma Owusu-Ansah, MD — University Hospitals Cleveland Medical Center
- Study coordinator: Umut Gurkan, PhD
- Email: umut@case.edu
- Phone: (216) 368-6447
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cerebrovascular Reactivity Testing with HD-DOT in Sickle Cell Patients
This study tests whether high-density diffuse optical tomography can measure brain blood flow and oxygen use in people with sickle cell disease, to see how these signals relate to stroke risk.
-
Adapting and testing PEN-Plus in Zambian primary care
Aiming to see if the PEN-Plus package can be adapted and used in two Zambian hospitals to better manage chronic diseases like heart disease, diabetes, hypertension, and sickle cell in primary care.
-
Newborn Sickle Cell Screening in Mozambique
We’re testing a three-part plan to help babies in Mozambique get diagnosed early for sickle cell disease and start care quickly.
-
Optimizing Hydroxyurea in Children with Sickle Cell in Africa
This study tests whether raising hydroxyurea to a maximum tolerated dose is safe and beneficial for Ugandan children with sickle cell anemia already taking a fixed daily dose.
-
Hematopoietic stem cell editing to treat sickle cell disease
This study tests whether a patient’s own blood stem cells can be edited to remove the sickle cell triggering gene and then returned to the patient.
-
Virtual reality options to help with VOC pain in adults with SCD
This study tests whether headset-based virtual reality can help reduce pain for adults with sickle cell disease during vaso-occlusive crises treated in an infusion center.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.